BrainWake guide · reviewed October 2026

Mushrooms

What a mushroom trip actually feels like — from colours getting richer to the sense of self dissolving — what decides whether it's beautiful or terrifying, and what psilocybin is doing in your brain at each stage.

The short version

  • With eyes open, the first thing is intensity: colours richer, textures sharper, light brighter. Then surfaces start to breathe and ripple.
  • Feelings come big and fast, and at higher doses the sense of being a separate self can dissolve into feeling one with everything.
  • Almost all of it runs through one serotonin receptor, 5-HT2A. Block that receptor and the trip doesn't happen.
  • A trip peaks about two hours in and lasts five or six.
  • Your mindset going in shapes it most: open and accepting predicts a good trip; preoccupied and apprehensive predicts a hard one.

What it feels like

The trip as it unfolds, what it does to seeing and to feeling, and the two directions it can go.

Over the hours

  • The first hour, Coming up: Psilocybin becomes psilocin in the body and levels climb.
  • About 2 hours, The peak: Psilocin is at its highest, and so are the effects.
  • 5–6 hours, Coming back: The effects fade over five and a half to six and a half hours on average — longer at higher doses.

What you see, as the dose rises

  • Threshold, Richer: Colour a little more saturated, light a little brighter.
  • Light, Alive: Textures sharpen and begin to move; bright lights glow.
  • Moderate, Breathing: Surfaces undulate, edges pulse and pattern grows out of texture; moving lights leave trails of separate afterimages.
  • Strong, Geometry: Geometric pattern spreads over anything textured, and music can shape it; sizes and shapes shift.
  • Very strong, Latticework: Brightly coloured, flowing latticework fills the whole field of view.

What it can feel like

  • Big feelings: Emotions arrive strong and fast; everything feels more dreamlike as the dose rises.
  • Time: Minutes stretch; past a few seconds, judging time falls apart.
  • Self: At higher doses, "all notion of self and identity dissolved away" — and a sense of being one with everything.
  • Awe: A mystical-type experience: unity, a sense of the sacred, of touching something true, beyond time and space, beyond words.
  • Meaning: Fourteen months after one supervised session, 58% of volunteers ranked it among the five most meaningful experiences of their lives.

It can also go the other way. People's accounts of their worst trips fall into fear, grief, thoughts of death, fear of going insane, isolation, physical distress and paranoia — often with the dread that it will never end. Yet of nearly 2,000 people describing their most difficult trip, 84% said they'd benefited from it.

What tips it? Going in open, accepting and surrendered predicted good and mystical-type experiences; going in preoccupied, apprehensive or confused predicted hard ones.

What's happening in the brain

One receptor, a visual cortex making its own patterns, and a self network coming apart. The model lights each one as you read.

One lock

Psilocin switches on the serotonin 5-HT2A receptor, packed onto large neurons across the cortex. Block it with another drug and the psychedelic effects vanish.

The patterns

Psilocybin suppresses the visual cortex's alpha rhythm, and the more it does, the stronger the visions. The geometry people see — lattices, cobwebs, tunnels, spirals — is the shape of the visual cortex itself: excite that sheet of neurons and it settles into stripes and hexagons, which, seen back through the way the eye maps onto it, are exactly those forms.

The self dissolving

Psilocybin quietened hubs like the thalamus and the cingulate, and the drop in medial prefrontal activity predicted how intense it felt. It blurs the boundaries between the brain's networks, most of all in the default mode network, which holds together your sense of self — and the change tracks the experience.

Fear, quietened

It lowered the amygdala's response to negative images, and the drop tracked a rise in good mood. Part of the warmth of a good trip may be the alarm going quiet.

Time

Intervals of seconds to minutes are timed by circuits in the basal ganglia and cerebellum. On psilocybin, reproducing intervals longer than about three seconds, or tapping along to a slow beat, falls apart.

Questions people ask

The things people wonder about tripping — answered.

Risks and staying safe

Low on physical risk; the risks are mostly in the mind and in what you do.

Physically, psilocybin is among the least toxic drugs — about a thousand times a typical dose would be needed to kill, against about ten for alcohol — and it doesn't typically lead to addiction. In a survey of 135,095 adults, psychedelic use wasn't linked to more mental health problems.

The real risks

  • A hard trip: The most likely problem. In one survey, 11% had put themselves or others at risk during their worst one.
  • Psychosis: It can worsen mental illness in people who have, or are predisposed to, psychotic disorders.
  • Lithium: In reports of psychedelics taken on lithium, nearly half described seizures.
  • The wrong mushroom: Misidentified wild mushrooms cause most mushroom deaths.
  • Lasting visuals: Uncommon, but visual disturbances can persist for months after.

Set and setting

  • Go in calm and open, with a clear intention.
  • A safe, familiar place, with someone sober you trust.
  • Skip it with a personal or family history of psychosis, or on lithium.
  • If it gets hard: it ends within hours, and letting go goes better than fighting it.

Check what you know

Five questions about what a trip is doing.

  • People tripping on mushrooms, LSD, during migraines and even when pressing on their eyes describe the same few shapes: lattices, cobwebs, tunnels, spirals. Why the same shapes? They're patterns the visual cortex makes itself when it's over-excited, distorted by how the eye maps onto it. An excited sheet of visual cortex settles into stripes and hexagons, which, through the eye-to-cortex map, look like these exact forms.
  • At the peak of a strong trip, someone says "I wasn't me any more — I was everything." What's happening in the brain? The default mode network, tied to the sense of self, is losing its boundaries. Psilocybin disrupted network boundaries most in the default mode network, tracking the experience, and ego dissolution rises with dose.
  • A researcher gives volunteers a drug that blocks the 5-HT2A receptor, then psilocybin. What happens? The trip mostly doesn't happen. Blocking 5-HT2A with ketanserin blocked psilocybin's effects, dose-dependently.
  • Two friends take the same dose. One goes in relaxed and curious; the other is stressed about work and worried about the trip. What does research predict? The relaxed, open one is more likely to have a good trip; the preoccupied one a harder one. Surrender and openness predicted positive, mystical-type experiences; preoccupation and apprehension predicted adverse ones.
  • During a trip, a song seems to go on for an hour. Why? Psilocybin disrupts the circuits that time intervals longer than a few seconds. Timing of seconds to minutes runs through basal ganglia and cerebellar circuits, and psilocybin impaired reproducing intervals over about three seconds.

Sources

  1. Unifying theories of psychedelic drug effects. Frontiers in Pharmacology, 2018.
  2. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology, 2004.
  3. Ego-dissolution and psychedelics: validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience, 2016.
  4. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 1998.
  5. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clinical Pharmacology & Therapeutics, 2023.
  6. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacology & Translational Science, 2021.
  7. The pharmacology of psilocybin. Addiction Biology, 2002.
  8. Visual trails: do the doors of perception open periodically?. PLoS Biology, 2011.
  9. Serotonergic hallucinogen-induced visual perceptual alterations. Current Topics in Behavioral Neurosciences, 2018.
  10. Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology, 2007.
  11. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 2015.
  12. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 2008.
  13. The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 2016.
  14. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. Journal of Psychopharmacology, 2016.
  15. Replication and extension of a model predicting response to psilocybin. Psychopharmacology, 2019.
  16. Psychedelics. Pharmacological Reviews, 2016.
  17. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. Journal of Neuroscience, 2013.
  18. A mathematical theory of visual hallucination patterns. Biological Cybernetics, 1979.
  19. Geometric visual hallucinations, Euclidean symmetry and the functional architecture of striate cortex. Philosophical Transactions of the Royal Society B, 2001.
  20. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 2012.
  21. Psilocybin desynchronizes the human brain. Nature, 2024.
  22. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 2015.
  23. What makes us tick? Functional and neural mechanisms of interval timing. Nature Reviews Neuroscience, 2005.
  24. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 2004.
  25. Psilocybin (magic mushrooms). US National Institute on Drug Abuse, 2024.
  26. Psychedelics not linked to mental health problems or suicidal behavior: a population study. Journal of Psychopharmacology, 2015.
  27. Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 2008.
  28. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018.
  29. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry, 2021.
  30. Mushroom poisoning epidemiology in the United States. Mycologia, 2018.
  31. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug and Alcohol Dependence, 2003.
  32. Predicting responses to psychedelics: a prospective study. Frontiers in Pharmacology, 2018.
  33. Mescal and Mechanisms of Hallucinations. University of Chicago Press, 1966.
  34. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics, 2017.
  35. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 2006.
  36. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 2011.
  37. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 2018.
  38. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 2021.
  39. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 2022.